High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease

Clinical Drug Investigation

Volumn 25, Issue 6, 2005, Pages 401-408

  Zuin, R ^a,c   Palamidese, A ^a   Negrin, R ^b   Catozzo, L ^b   Scarda, A ^a   Balbinot, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c Divisione Pneumologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INTERLEUKIN 8; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG AUSCULTATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH PAIN;

EID: 22544436397     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525060-00005     Document Type: Article

References (19)

1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77-121
2. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8 (8): 1398-420
3. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320 (6): 365-76
4. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146 (4): 1067-83
5. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154 (3 Pt 1): 813-6
6. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989; 140 (2): 531-54
7. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16 (2): 253-62
8. Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22 (2): 209-21
9. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23 (4): 629-36
10. Kharazmi A. The anti-inflammatory properties of N-acetylcysteine. Eur Respir Rev 1992; 2 (7): 32-4
11. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6 (6): 593-7
12. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral NMed acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18 (1): 41-7
13. Kasielski M, Nowak D. Long-term administration of Npulmonary acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95 (6): 448-56
14. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J Biol Chem 1996; 271 (23): 13422-9
15. van Beurden WJ, Smeenk FW, Harff GA, et al. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch Chest Dis 2003; 59 (4): 273-80
16. Malo O, Sauleda J, Busquets X, et al. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2002; 38 (4): 172-6
17. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163 (2): 349-55
18. Vestbo J, Prescott E, Lange P. Association of chronic mucous hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153 (5): 1530-5
19. Allegra L, Blasi F, Capone P, et al. Proprietà mucoattive ed antiossidanti della NAC (N-acetilcisteina) ad alte dosi. G Ital Mal Torace 2002; 56 (3): 193-202